301075.SZ
多瑞医药
SZSE · C 制造业 · CN
CNY 53.75
+0.09%Year over year
Reported trailing growth
- Revenue
- -35.2%
- EBITDA
- —
- EBIT
- -18.6%
- EPS
- -33.1%
- Free cash flow
- -48.8%
- Operating cash flow
- +5.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -27.3%
- EBITDA
- -34.7%
- EBIT
- -49.7%
- Net income
- -63.0%
- EPS
- -63.3%
- Free cash flow
- -36.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026